Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution

Ultrasensitive Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine for Inhalation Solution

In cystic fibrosis, there is a critical need for better predictors of treatment response. The investigators have identified a panel of white blood cell biomarkers which can be directly measured as a blood test in subjects with cystic fibrosis. These biomarkers predict reduction of airway inflammation and infection more accurately than lung function testing, in patients receiving intravenous antibiotic therapy. In the current study, we hypothesize that this panel of gene biomarkers which can be readily measured from peripheral blood will sensitively predict changes in inflammation when patients receive inhaled antibiotic therapy, specifically Cayston (or inhaled aztreonam lysine). Patients enrolled in the study will have blood drawn before and after a month of inhaled Cayston, in order to test whether genes predict response to Cayston therapy more robustly than do standard measures such as lung function tests.

Inclusion Criteria:

• Documented diagnosis of cystic fibrosis
• Age 18 years old or greater
• FEV1 percent predicted greater than 25%
• Ability to perform reproducible pulmonary function tests and produce sputum spontaneously
• Chronic bacterial colonization with Pseudomonas aeruginosa with 2 positive cultures in previous 2 years.
• Chronically stable pulmonary condition without evidence of acute pulmonary exacerbation within 14 days prior to screening
• Starting Cayston cycle as part of clinical care.

Exclusion Criteria:

• Presence of a condition or abnormality that, in the opinion of the Principal Investigator (PI), would compromise the safety of the patient or the quality of the data.
• Aztreonam allergy, bronchospasm or other contraindication to use of aztreonam.
• Signs and symptoms of acute pulmonary exacerbation at the time of enrollment or during study.
• Active infection and treatment for non-tuberculous mycobacteria.
• Concomitant use of systemic steroids.
• Use of inhaled antimicrobial agents with activity against Pseudomonas aeruginosa within 28 days prior to Visit 1.